Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunity & Ageing
Published in: Immunity & Ageing 1/2007

Open Access 01-12-2007 | Research

NK cell compartment in patients with coronary heart disease

Authors: Łukasz Hak, Jolanta Myśliwska, Joanna Więckiewicz, Krzysztof Szyndler, Piotr Trzonkowski, Janusz Siebert, Andrzej Myśliwski

Published in: Immunity & Ageing | Issue 1/2007

Login to get access

Abstract

Background

Viral and bacterial infections have been considered as a risk factor for Coronary Heart Disease (CHD). NK cells, as a first line of defense against those infections, may play a role in CHD development. Thus, the main aim of our study was to determine NK cell compartment in patients with CHD undergoing coronary artery by-pass grafting.

Results

Ninety three patients with CHD were included into the study; the control group consisted of 49 healthy volunteers. As compared to controls, CHD patients had lower NK cytotoxic activity. CHD group had also a decreased absolute number and percentage of total NK cells and CD3-CD56dim cytotoxic NK subset. In addition, we observed tendency toward lower percentage of the CD3-CD56bright regulatory NK subset and CD3-CD56+IFN-γ+ cells in CHD patients.

Conclusion

These data indicate that CHD is associated with an impairment of NK cells compartment.
Appendix
Available only for authorised users
Literature
1.
Garcia-Penarrubia P, Koster FT, Kelley RO, McDowell TD, Bankhurst AD: Antibacterial activity of human natural killer cells. J Exp Med. 1989, 169 (1): 99-113. 10.1084/jem.169.1.99.PubMed
2.
Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol. 2001, 22 (11): 633-640. 10.1016/S1471-4906(01)02060-9.PubMed
3.
Sedlmayr P, Schallhammer L, Hammer A, Wilders-Truschnig M, Wintersteiger R, Dohr G: Differential phenotypic properties of human peripheral blood CD56dim+ and CD56bright+ natural killer cell subpopulations. Int Arch Allergy Immunol. 1996, 110 (4): 308-313.PubMed
4.
Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G, Sykora KW, Schmidt RE: CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol. 2001, 31 (10): 3121-3127. 10.1002/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4.PubMed
5.
Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA: Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001, 97 (10): 3146-3151. 10.1182/blood.V97.10.3146.PubMed
6.
Morel PA, Oriss TB: Crossregulation between Th1 and Th2 cells. Crit Rev Immunol. 1998, 18 (4): 275-303.PubMed
7.
Ross R: Atherosclerosis is an inflammatory disease. Am Heart J. 1999, 138 (5 Pt 2): S419-420. 10.1016/S0002-8703(99)70266-8.PubMed
8.
Streblow DN, Orloff SL, Nelson JA: Do pathogens accelerate atherosclerosis?. J Nutr. 2001, 131 (10): 2798S-2804S.PubMed
9.
Ouchi K: Chlamydia pneumoniae and atherosclerosis. Jpn J Infect Dis. 1999, 52 (6): 223-227.PubMed
10.
Zhou YF, Yu ZX, Wanishsawad C, Shou M, Epstein SE: The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Biochem Biophys Res Commun. 1999, 256 (3): 608-613. 10.1006/bbrc.1999.0387.PubMed
11.
Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE: Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis. 2001, 156 (1): 23-28. 10.1016/S0021-9150(00)00608-0.PubMed
12.
Liuba P, Karnani P, Pesonen E, Paakkari I, Forslid A, Johansson L, Persson K, Wadstrom T, Laurini R: Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation. 2000, 102 (9): 1039-1044.PubMed
13.
Ogata K, Yokose N, Tamura H, An E, Nakamura K, Dan K, Nomura T: Natural killer cells in the late decades of human life. Clin Immunol Immunopathol. 1997, 84 (3): 269-75. 10.1006/clin.1997.4401.PubMed
14.
Ogata K, An E, Shioi Y, Nakamura K, Luo S, Yokose N, Minami S, Dan K: Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol. 2001, 124 (3): 392-397. 10.1046/j.1365-2249.2001.01571.x.PubMedCentralPubMed
15.
Mocchegiani E, Malavolta M: NK and NKT cell functions in immunosenescence. Aging Cell. 2004, 3 (4): 177-84. 10.1111/j.1474-9728.2004.00107.x.PubMed
16.
Mariani E, Roda P, Mariani AR, Vitale M, Degrassi A, Papa S, Facchini A: Age-associated changes in CD8+ and CD16+ cell reactivity: clonal analysis. Clin Exp Immunol. 1990, 81 (3): 479-84.PubMedCentralPubMed
17.
Kutza J, Murasko DM: Effects of aging on natural killer cell activity and activation by interleukin-2 and IFN-alpha. Cell Immunol. 1994, 155 (1): 195-204. 10.1006/cimm.1994.1112.PubMed
18.
Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D, Marcato A, Passeri G, Ortolani C, Forti E: Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood. 1993, 82 (9): 2767-2773.PubMed
19.
Mavoungou E, Poaty-Mavoungou V, Toure FS, Sall A, Delicat A, Yaba P, Mandeme Y, Nabias R, Lansoud-Soukate J: Impairment of natural killer cell activity in Chlamydia trachomatis infected individuals. Trop Med Int Health. 1999, 4 (11): 719-727. 10.1046/j.1365-3156.1999.00479.x.PubMed
20.
Morishima C, Paschal DM, Wang CC, Yoshihara CS, Wood BL, Yeo AE, Emerson SS, Shuhart MC, Gretch DR: Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology. 2006, 43 (3): 573-580. 10.1002/hep.21073.PubMed
21.
Albright JW, Albright JF: Impaired natural killer cell function as a consequence of aging. Exp Gerontol. 1998, 33 (1–2): 13-25. 10.1016/S0531-5565(97)00099-5.PubMed
22.
Trzonkowski P, Mysliwska J, Szmit E, Wieckiewicz J, Lukaszuk K, Brydak LB, Machala M, Mysliwski A: Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination–an impact of immunosenescence. Vaccine. 2003, 21 (25–26): 3826-3836. 10.1016/S0264-410X(03)00309-8.PubMed
23.
Mysliwska J, Trzonkowski P, Szmit E, Brydak LB, Machala M, Mysliwski A: Immunomodulating effect of influenza vaccination in the elderly differing in health status. Exp Gerontol. 2004, 39 (10): 1447-1458. 10.1016/j.exger.2004.08.005.PubMed
24.
Georgeson GD, Szony BJ, Streitman K, Kovacs A, Kovacs L, Laszlo A: Natural killer cell cytotoxicity is deficient in newborns with sepsis and recurrent infections. Eur J Pediatr. 2001, 160 (8): 478-482. 10.1007/s004310100773.PubMed
25.
Bruunsgaard H, Pedersen AN, Schroll M, Skinhoj P, Pedersen BK: Decreased natural killer cell activity is associated with atherosclerosis in elderly humans. Exp Gerontol. 2001, 37 (1): 127-136. 10.1016/S0531-5565(01)00162-0.PubMed
26.
Jonasson L, Backteman K, Ernerudh J: Loss of natural killer cell activity in patients with coronary artery disease. Atherosclerosis. 2005, 183 (2): 316-321. 10.1016/j.atherosclerosis.2005.03.011.PubMed
27.
Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, Pena J, Solana R: NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol. 1999, 34 (2): 253-265. 10.1016/S0531-5565(98)00076-X.PubMed
28.
Redpath S, Angulo A, Gascoigne NR, Ghazal P: Murine cytomegalovirus infection down-regulates MHC class II expression onmacrophages by induction of IL-10. J Immunol. 1999, 162 (11): 6701-6707.PubMed
29.
Caspar-Bauguil S, Puissant B, Nazzal D, Lefevre JC, Thomsen M, Salvayre R, Benoist H: Chlamydia pneumoniae induces interleukin-10 production that down-regulates major histocompatibility complex class I expression. J Infect Dis. 2000, 182 (5): 1394-1401. 10.1086/315856.PubMed
30.
Akuffo H, Alexis A, Eidsmo L, Saed A, Nylen S, Maasho K: Natural killer cells in cross-regulation of IL-12 by IL-10 in Leishmania antigen-stimulated blood donor cells. Clin Exp Immunol. 1999, 117 (3): 529-534. 10.1046/j.1365-2249.1999.00994.x.PubMedCentralPubMed
31.
de Waal Malefyt R, Yssel H, de Vries JE: Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol. 1993, 150 (11): 4754-4765.PubMed
32.
Krishnaraj R, Bhooma T: Cytokine sensitivity of human NK cells during immunosenescence. 2. IL2-induced interferon gamma secretion. Immunol Lett. 1996, 50 (1–2): 59-63. 10.1016/0165-2478(96)02519-9.PubMed
33.
Wang EC, Taylor-Wiedeman J, Perera P, Fisher J, Borysiewicz LK: Subsets of CD8+, CD57+ cells in normal, healthy individuals: correlations with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses. Clin Exp Immunol. 1993, 94 (2): 297-305.PubMedCentralPubMed
34.
Jonasson L, Tompa A, Wikby A: Expansion of peripheral CD8+ T cells in patients with coronary artery disease: relation to cytomegalovirus infection. J Intern Med. 2003, 254 (5): 472-478. 10.1046/j.1365-2796.2003.01217.x.PubMed
35.
Autran B, Leblond V, Sadat-Sowti B, Lefranc E, Got P, Sutton L, Binet JL, Debre P: A soluble factor released by CD8+CD57+ lymphocytes from bone marrowtransplanted patients inhibits cell-mediated cytolysis. Blood. 1991, 77 (10): 2237-2241.PubMed
36.
Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF: CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol. 2004, 173 (10): 6418-6426.PubMed
37.
Mysliwska J, Bryl E, Zorena K, Balon J, Foerster J, Mysliwski A: Overactivity of tumor necrosis factor-alpha but not interleukin 6 is associated with low natural killer cytotoxic activity in the elderly. Gerontology. 1997, 43 (3): 158-167.PubMed
38.
Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M: Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003, 108 (19): 2317-2322. 10.1161/01.CIR.0000097109.90783.FC.PubMed
Metadata
Title
NK cell compartment in patients with coronary heart disease
Authors
Łukasz Hak
Jolanta Myśliwska
Joanna Więckiewicz
Krzysztof Szyndler
Piotr Trzonkowski
Janusz Siebert
Andrzej Myśliwski
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Immunity & Ageing / Issue 1/2007
Electronic ISSN: 1742-4933
DOI
https://doi.org/10.1186/1742-4933-4-3

Other articles of this Issue 1/2007

Immunity & Ageing 1/2007 Go to the issue

Review

Role of persistent CMV infection in configuring T cell immunity in the elderly

Short report

Zinc and ageing: third Zincage conference

Review

Pathophysiology of ageing, longevity and age related diseases

Short report

Zinc-bound metallothioneins and immune plasticity: lessons from very old mice and humans

Hypothesis

The Interleukin-6 inflammation pathway from cholesterol to aging – Role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases

Review

Challenges for vaccination in the elderly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits